- Home
- PCVX vs BRKR Comparison
PCVX vs BRKR Comparison
Compare PCVX & BRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCVX
- BRKR
- Stock Information
- Founded
- PCVX 2013
- BRKR 1991
- Country
- PCVX United States
- BRKR United States
- Employees
- PCVX N/A
- BRKR N/A
- Industry
- PCVX Biotechnology: Pharmaceutical Preparations
- BRKR Biotechnology: Laboratory Analytical Instruments
- Sector
- PCVX Health Care
- BRKR Industrials
- Exchange
- PCVX Nasdaq
- BRKR Nasdaq
- Market Cap
- PCVX 13.2B
- BRKR 9.2B
- IPO Year
- PCVX 2020
- BRKR 2000
- Fundamental
- Price
- PCVX $78.14
- BRKR $61.26
- Analyst Decision
- PCVX Strong Buy
- BRKR Buy
- Analyst Count
- PCVX 9
- BRKR 13
- Target Price
- PCVX $149.38
- BRKR $75.67
- AVG Volume (30 Days)
- PCVX 1.1M
- BRKR 1.4M
- Earning Date
- PCVX 02-25-2025
- BRKR 02-11-2025
- Dividend Yield
- PCVX N/A
- BRKR 0.33%
- EPS Growth
- PCVX N/A
- BRKR N/A
- EPS
- PCVX N/A
- BRKR 2.06
- Revenue
- PCVX N/A
- BRKR $3,241,300,000.00
- Revenue This Year
- PCVX N/A
- BRKR $15.23
- Revenue Next Year
- PCVX N/A
- BRKR $7.52
- P/E Ratio
- PCVX N/A
- BRKR $30.54
- Revenue Growth
- PCVX N/A
- BRKR 15.00
- 52 Week Low
- PCVX $58.10
- BRKR $48.07
- 52 Week High
- PCVX $121.06
- BRKR $94.86
- Technical
- Relative Strength Index (RSI)
- PCVX 32.14
- BRKR 58.41
- Support Level
- PCVX $80.10
- BRKR $58.78
- Resistance Level
- PCVX $81.70
- BRKR $64.64
- Average True Range (ATR)
- PCVX 3.12
- BRKR 1.98
- MACD
- PCVX -0.13
- BRKR 0.39
- Stochastic Oscillator
- PCVX 5.68
- BRKR 59.23
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.